Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Odronextamabe para linfomas recidivantes e refratários de grandes células B antes do CAR-T

17 de novembro de 2026 atualizado por: University of Washington

Odronextamabe para linfomas recidivantes/refratários de grandes células B antes de terapias direcionadas ao linfoma definitivo

This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.

Visão geral do estudo

Descrição detalhada

OUTLINE:

Patients receive odronextamab intravenously (IV) on days 1, 2, 8, 9, 15 and 16 of cycle 1 (dose step-up), and on days 1, 8 and 15 of cycles 2-4 and then once every other week of remaining cycles. Cycles repeat every 21 days for the first 4 cycles, then every other week for up to a total of 12 months (including the first 2 cycles). After 2 cycles, patients undergo leukapheresis followed by lymphodepletion and CAR-T infusion per standard of care. If there is a significant delay of leukapheresis, patients may receive up to 12 additional weeks of treatment. Patients who achieve CR after cycle 2 may opt out of leukapheresis and CAR-T cell infusion and may continue to receive odronextamab in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT), collection of blood and oral or rectal swab samples and tissue biopsy throughout the study. Additionally, patients may undergo lumbar puncture and bone marrow aspiration and/or biopsy on study.

After completion of study treatment, patients are followed till 90 days or the initiation of the next lymphoma directed therapy for toxicity check, and total duration of follow-up is up to 5 years.

Tipo de estudo

Intervencional

Inscrição (Estimado)

27

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Recrutamento
        • Fred Hutch/University of Washington Cancer Consortium
        • Investigador principal:
          • Mengyang Di, MD, PhD
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Histologically confirmed large B cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from indolent lymphoma, follicular lymphoma (FL) grade 3B
  • Measurable disease, defined as at least one measurable lesion ≥ 15 mm on PET, CT, or magnetic resonance imaging (MRI) within one month of screening, according to the International Working Group consensus response evaluation criteria in lymphoma
  • Prior frontline therapy for large B cell lymphoma must have failed the patient, and criteria must be met for receiving commercial axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel) per Food and Drug Administration (FDA) label
  • Age ≥ 18 years
  • Capable of understanding and providing a written informed consent
  • Prior treatment with an anti-CD20 antibody therapy
  • Eastern Cooperative Oncology Group performance status of 0-1; we allow enrollment of patients with a performance status of 2 if it is attributed to lymphoma per discretion of the treating physician or principal investigator (PI)
  • Creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault equation
  • Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome
  • Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x the ULN
  • Adequate pulmonary function, defined as ≤ grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% on room air
  • Adequate cardiac function, defined as left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
  • Platelet count ≥ 75 x 10^9 /L
  • Hemoglobin (Hg) level ≥ 9 g/dL
  • Absolute neutrophil count (ANC) ≥ 1 x 10^9 /L
  • Patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L
  • Patients with bone marrow involvement or splenic sequestration: Hg ≥ 7.0 g/dL
  • Patients with bone marrow involvement or splenic sequestration: ANC ≥ 0.5 x 10^9 /L
  • Negative serum pregnancy test within 2 days of initiating odronextamab for women of childbearing potential (WOCBP), defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
  • Fertile male and WOCBP patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the CAR T-cell infusion
  • Patients must not provide egg or sperm donation until at least 6 months after the completion of the last dose of Odron

Exclusion Criteria:

  • Detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of cerebrospinal fluid malignant cells or brain metastases. Patients with a history of secondary central nervous system (CNS) lymphoma may be eligible provided that there has been no evidence of CNS disease from lymphoma for at least 3 months at the time of screening
  • History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
  • Standard anti-neoplastic chemotherapy (non-biologic) within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
  • Standard radiotherapy within 2 weeks of first administration of study drug
  • Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy, unless all the following are met: disease responded to prior bispecific therapy (CR or PR per Lugano criteria) and did not experience disease progression within 12 months of the last dose of prior bispecific therapy, and the tumor must still express CD20 (CD20 examination per standard of care [SOC])
  • Allogeneic stem cell transplantation
  • Any CAR-T cell therapy
  • Patients may not be receiving other investigational agents
  • Treatment with rituximab, alemtuzumab, or other investigational or commercial biologic agent within 2 weeks prior to first administration of study drug
  • Immunosuppressive therapy (other than biologic) within 2 weeks of first administration of study drug
  • Treatment with an investigational non-biologic agent within 2 weeks of first administration of study drug
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition of study drug
  • History of hypersensitivity to any compound in the tetracycline antibiotics group
  • Concurrent active malignancy for which the patient is receiving systemic treatment, unless approved by PI
  • Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection
  • Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) and/or significant pulmonary disease (e.g., obstructive pulmonary disease and history of symptomatic bronchospasm)
  • Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent. A short course of corticosteroid for lymphoma disease control during screening is allowed
  • Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 400) or chronic infection with hepatitis B virus or hepatitis C virus. Patients with hepatitis B (hepatitis B surface antigen positive [HepBsAg+]) with controlled infection were permitted upon consultation with the physician managing the infection
  • Known hypersensitivity to both allopurinol and rasburicase
  • Pregnant or breast-feeding women
  • Administration of live vaccination within 28 days of first administration of study drug

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment (odronextamab)

Patients receive odronextamab IV based on the following schedules:

  • Step-up dosing during cycle 1: 0.2 mg on C1D1, 0.5 mg on C1D2, 2 mg on C1D8 and C1D9, respectively, and 10 mg on C1D15 and C1D16, respectively (0.7/4/20 regimen).
  • Dosing during cycles 2-4: Odron will be given at 160 mg weekly.
  • Once every other week at 320 mg of remaining cycles.

Please see the Detailed Description for additional information.

Undergo bone marrow biopsy

Outros nomes:
  • Biópsia de Medula Óssea
  • Biópsia, Medula Óssea

Ancillary studies

Undergo bone marrow aspiration

Undergo lumbar puncture

Outros nomes:
  • LP
  • Punção lombar

Undergo PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • imagens espectroscópicas de ressonância magnética de prótons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Undergo PET/CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)

Undergo tissue biopsy

Outros nomes:
  • Bx

Undergo leukapheresis

Outros nomes:
  • Leucocitoférese
  • Leucoférese Terapêutica
  • Aférese Adsortiva de Leucócitos
  • Aférese de redução de glóbulos brancos

Given IV

Outros nomes:
  • REGN1979
  • Anticorpo Monoclonal Biespecífico Anti-CD20 x Anti-CD3 REGN1979
  • OMS 11035

Undergo collection of blood and oral or rectal swab samples

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo CAR-T cell therapy

Outros nomes:
  • Infusão CAR T
  • Terapia CAR T
  • Terapia de células T CAR
  • Infusão de células T do receptor de antígeno quimérico

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Failure to undergo leukapheresis
Prazo: Up to 5 years

Will include failures due to disease progression or adverse events (AEs) due to odronextamab (Odron), or requirement of other lymphoma-directed therapy for bridging before leukapheresis due to lack of response. Will report the total number and percentage with 95% confidence interval (CI).

Up to 5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Receipt of chimeric antigen receptor T-cell therapy (CAR-T)
Prazo: Up to 5 years

Will estimate the total number and percentage with 95% CI of patients who receive CAR-T cell infusion. Patients who achieve complete response (CR) after 2 cycles of Odron and opt out of leukapheresis will be excluded from the estimation of the percentage. Will also report the reasons why patients do not eventually receive CAR-T.

Up to 5 years
Overall response rate (ORR) following bridging prior to CAR-T infusion
Prazo: Up to 5 years

ORR includes CR, partial response, stable disease. Will report the total number and percentage with 95% CI of patients who achieve response on positron emission tomography/computed tomography (PET/CT) scans before CAR-T cell infusion. Patients who receive CAR-T cell infusion will be included in the estimation of this percentage.

Up to 5 years
Progression free survival (PFS) following CAR-T infusion
Prazo: Up to 2 years

Will estimate the median with interquartile range of the progression free duration. Will also report the percentage with 95% CI.

Up to 2 years
CR rate
Prazo: At 1 month after CAR-T

Will report the total number and percentage with 95% CI of patients who achieve CR on the PET/CT scans following CAR-T cell infusion.

At 1 month after CAR-T
PFS in patients who achieve CR after 2 cycles of Odron, choose to opt out of CAR-T, and receive up to a total of 12 months of Odron
Prazo: Up to 5 years

Will report the median duration of PFS with 95% CI in this group of patients.

Up to 5 years
Incidence of AEs
Prazo: Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first

All AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome will be graded by the American Society for Transplantation and Cellular Therapy Consensus Grading systems. Will report the rate and grade of each AE, including unsuccessful CAR-T production.

Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de setembro de 2025

Conclusão Primária (Estimado)

10 de abril de 2028

Conclusão do estudo (Estimado)

11 de abril de 2033

Datas de inscrição no estudo

Enviado pela primeira vez

14 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de janeiro de 2025

Primeira postagem (Real)

20 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever